This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Calendar: Key FDA Action Dates

Vion Pharmaceuticals (VION.OB)
Drug/indication: Onrigin for acute myelogenous leukemia
FDA decision date: Dec. 12

If approved, Onrigin would be used to induce remission in elderly AML patients.

Now, an updates of recently announced FDA approval decisions:

Savient Pharmaceuticals (SVNT)
Drug/indication: Krystexxa for gout
FDA decision date: Aug. 1

The FDA declined to approve Krystexxa, citing concerns about the way the drug is manufactured. The FDA rejection came despite a recommendation for approval from an advisory panel in June. Savient plans to respond to the FDA's concerns in early 2010.

BioDelivery Sciences (BDSI)
Drug/indication: Onsolis for breakthrough cancer pain
FDA decision date: June 15

The FDA approved Onsolis on July 16.

AMAG Pharmaceuticals (AMAG)
Drug/Indication: Feraheme for anemia due to chronic kidney disease
FDA decision date: June 26

The FDA approved Feraheme on June 30.

Labopharm (DDSS)
Drug/indication: DDS-04A for depression
FDA decision date: July 18

The FDA declined to approve DDS-04A on July 20, citing problems found during an inspection of the drug's manufacturing plant. Labopharm is working to address and correct the manufacturing issues and will submit a response to the FDA.

United Therapeutics (UTHR)
Drug/indication: Tyvaso for pulmonary arterial hypertension
FDA decision date: July 30

The FDA approved Tyvaso on July 30.

Advanced Life Sciences (ADLS.OB)
Drug/indication: Restanza for community-acquired pneumonia
FDA decision date: July 31

The FDA rejected Restanza on July 31. The company said it will need to conduct a new clinical trial in order to get the drug approved.

-- Reported by Adam Feuerstein in Boston
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
AUXL $36.47 -0.16%
TSPT $30.00 0.67%
CTIC $1.60 0.00%
ACOR $32.73 0.00%

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs